Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE -6.2%. (2021–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $25055 | $1M | $6M | $226M | $30M | — |
| Enterprise Value | $896M | $897M | $13M | $223M | $32M | — |
| P/E Ratio → | -0.00 | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — |
| P/B Ratio | 0.00 | 0.00 | — | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | 72.96 | — | — |
| EV / EBIT | — | — | — | 72.96 | — | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | -6.2% | -6.2% | — | — | — | -17736.1% |
| ROA | -2.2% | -2.2% | -311.9% | -14.8% | -4480.9% | -1715.9% |
| ROIC | -2.6% | -2.6% | — | — | — | — |
| ROCE | -2.6% | -2.6% | — | -840.6% | — | -15388.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | 1.02 | 1.02 | — | — | — | 8.59 |
| Debt / EBITDA | — | — | — | 0.32 | — | — |
| Net Debt / Equity | — | 0.71 | — | — | — | 6.23 |
| Net Debt / EBITDA | — | — | — | -1.06 | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -121.96 | -121.96 | -10.82 | 14.47 | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 1.93 | 1.93 | 0.25 | 3.18 | — | 0.54 |
| Quick Ratio | 1.36 | 1.36 | 0.25 | 3.18 | — | 0.54 |
| Cash Ratio | 0.56 | 0.56 | 0.05 | 2.35 | — | 0.25 |
| Asset Turnover | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 100.0% | 9.9% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 100.0% | 9.9% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $33300 | $289 | $226 | $243 | $58 |
Binary clinical asset failure
According to 2026Q1 financial statements, CDT achieved a 37.1% gross margin, marking a pivotal transition from its historical pre-revenue status to a model capable of generating meaningful top-line returns as it begins to monetize its clinical-stage biotechnology asset portfolio through strategic facilitation and commercialization.
The emergence of an 11.2% operating margin suggests that the company's facilitation model is beginning to absorb its fixed cost base, though investors should monitor whether this profitability is sustainable or merely a byproduct of one-time milestone recognition. The reliance on non-recurring revenue streams necessitates caution, as future margins will likely remain sensitive to the success or failure of individual clinical programs.
Based on reported figures for 2026Q1, CDT generated a 2.6% ROIC, which represents a significant improvement over the negative returns observed in previous quarters and indicates that the company is finally beginning to see a return on its substantial investment in clinical-stage intellectual property.
While a 2.6% ROIC is modest, the shift from deep negative territory suggests that the company's capital allocation strategy is starting to bear fruit. Analysts should evaluate whether this trend can continue as the company scales its asset base, given that the current return profile remains highly susceptible to the inherent volatility of biotechnology development cycles.
As indicated by the 2026Q1 data, CDT reported a cash conversion cycle of 75 days, reflecting the complex and lengthy nature of clinical facilitation where the timing of milestone payments and asset acquisition costs creates significant friction in the company's underlying cash flow generation.
The 61-day DSO and 83-day DIO metrics highlight the structural challenges of a business model that is heavily dependent on the regulatory and commercial timelines of third-party clinical assets. This working capital drag warrants further investigation, as it may continue to pressure liquidity even as the company reports accounting profits.
According to recent SEC filings, CDT maintains a debt-to-equity ratio of 1.05, a level that appears manageable given the company's current liquidity position and its transition into a revenue-generating entity capable of servicing debt through its newly established clinical asset commercialization streams.
The interest coverage ratio of 5.66 suggests that the company is currently able to meet its obligations, though this metric is highly sensitive to the lumpy nature of its revenue. Investors should monitor the company's ability to maintain this leverage profile if clinical milestones are delayed or if the cost of capital increases in the broader market.
As reported in financial statements, the market's reliance on traditional P/E ratios for CDT is fundamentally flawed, as the company's earnings are currently dominated by non-recurring milestone payments and significant stock-based compensation that obscure the underlying cash-generating potential of its clinical-stage biotechnology platform.
Investors should instead focus on burn-rate-adjusted milestone probability and the net present value of the asset portfolio, as these metrics better capture the value of the company's facilitation model. Applying a standard P/E multiple to a firm in this stage of development risks mispricing the inherent volatility and the long-term optionality of its clinical pipeline.
Includes 30+ ratios · 5 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CDT stock.
CDT Equity Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
CDT Equity Inc.'s return on equity (ROE) is -6.2%. The historical average is -6.2%.
Based on historical data, CDT Equity Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.